Suppr超能文献

卡格列净改善冠状动脉微血管舒张功能,并增加心肌绝对血流量,而不依赖于血管生成。

Canagliflozin improves coronary microvascular vasodilation and increases absolute blood flow to the myocardium independent of angiogenesis.

机构信息

Division of Cardiothoracic Surgery, Department of Surgery, Cardiovascular Research Center, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI.

Division of Cardiothoracic Surgery, Department of Surgery, Cardiovascular Research Center, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI.

出版信息

J Thorac Cardiovasc Surg. 2023 Dec;166(6):e535-e550. doi: 10.1016/j.jtcvs.2023.08.017. Epub 2023 Aug 20.

Abstract

OBJECTIVES

Sodium-glucose cotransporter-2 inhibitor, canagliflozin, improves myocardial perfusion to ischemic territory without accompanying changes in vascular density. We aimed to (1) characterize effects on angiogenic pathways, (2) use multiomics to identify gene expression and metabolite profiles relevant to regulation of myocardial blood flow, and (3) investigate drug effect on coronary microvascular reactivity.

METHODS

A nondiabetic swine model of chronic myocardial ischemia and nondiabetic rat model were used to study functional and molecular effects of canagliflozin on myocardium and in vitro microvascular reactivity.

RESULTS

Canagliflozin resulted in increased coronary microvascular vasodilation and decreased vasoconstriction (P < .05) without changes in microvascular density (P > .3). Expression of the angiogenic modulator, endostatin, increased (P = .008), along with its precursor, collagen 18 (P < .001), and factors that increase its production, including cathepsin L (P = .004). Endostatin and collagen 18 levels trended toward an inverse correlation with blood flow to ischemic territory at rest. Proangiogenic fibroblast growth factor receptor was increased (P = .03) and matrix metalloproteinase-9 was decreased (P < .001) with canagliflozin treatment. Proangiogenic vascular endothelial growth factor A (P = .13), Tie-2 (P = .10), and Ras (P = .18) were not significantly altered. Gene expression related to the cardiac renin-angiotensin system was significantly decreased.

CONCLUSIONS

In chronic myocardial ischemia, canagliflozin increased absolute blood flow to the myocardium without robustly increasing vascular density or proangiogenic signaling. Canagliflozin resulted in altered coronary microvascular reactivity to favor vasodilation, likely through direct effect on vascular smooth muscle. Downregulation of cardiac renin-angiotensin system demonstrated local regulation of perfusion. VIDEO ABSTRACT.

摘要

目的

钠-葡萄糖共转运蛋白 2 抑制剂坎格列净可改善缺血区心肌灌注,而不伴有血管密度的变化。本研究旨在:(1)描述对血管生成途径的影响;(2)利用多组学技术确定与调节心肌血流相关的基因表达和代谢物特征;(3)研究药物对冠状动脉微血管反应性的影响。

方法

采用非糖尿病性慢性心肌缺血猪模型和非糖尿病性大鼠模型,研究坎格列净对心肌的功能和分子作用,以及在体外微血管反应性。

结果

坎格列净导致冠状动脉微血管扩张增加,血管收缩减少(P<.05),而微血管密度无变化(P>.3)。血管生成调节剂内皮抑素的表达增加(P=.008),其前体胶原 18 也增加(P<.001),以及增加其产生的因子如组织蛋白酶 L 也增加(P=.004)。内皮抑素和胶原 18 水平与静息时缺血区的血流呈负相关趋势。坎格列净治疗后,促血管生成的成纤维细胞生长因子受体增加(P=.03),基质金属蛋白酶-9 减少(P<.001)。促血管生成的血管内皮生长因子 A(P=.13)、Tie-2(P=.10)和 Ras(P=.18)均无明显改变。心脏肾素-血管紧张素系统相关基因表达显著降低。

结论

在慢性心肌缺血中,坎格列净增加了心肌的绝对血流,而没有明显增加血管密度或促血管生成信号。坎格列净导致冠状动脉微血管对血管舒张的反应性发生改变,可能通过对血管平滑肌的直接作用。心脏肾素-血管紧张素系统的下调表明了局部灌注的调节。视频摘要。

相似文献

引用本文的文献

本文引用的文献

5
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净治疗射血分数保留的心力衰竭。
N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27.
6
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.恩格列净治疗心力衰竭的心血管和肾脏结局。
N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.
8
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.卡格列净与 2 型糖尿病和肾病患者的肾脏结局。
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验